CD8A and neoplasm: In the CheckMate-025, -010, and -009 trials, the tumor mutation burden and CD8+ T cell infiltration level were not predictive of second-line nivolumab monotherapy in patients previously treated with tyrosine kinase inhibitor (5–7).